Trial Profile
A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Feb 2023
Price :
$35
*
At a glance
- Drugs Quetmolimab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors EA Pharma; Eisai Co Ltd
- 18 Feb 2021 Results published in the Journal of Gastroenterology and Hepatology
- 17 Jul 2018 Status changed from active, no longer recruiting to completed.
- 10 Mar 2017 Status changed from recruiting to active, no longer recruiting.